{
  "docId": "019de075-e341-775b-a82c-decdaeb5c03e",
  "docSlug": "c5ed60c4cc85a094dbae2fa13cb26a34",
  "documentTitle": "Alkermes | Investor Presentation Deck | 37 slides",
  "authorId": "alkermes",
  "authorName": "Mural Oncology",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 37,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The diagram illustrates the interaction between T cells, tumor cells, and cytokines (IL-2, IL-12, IL-18) and the mechanism of checkpoint inhibitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/8",
  "deckHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e",
  "deckJsonHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json",
  "deckAnchorHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.06,
        "y": 0.235
      },
      "kind": "image",
      "text": "Diagram showing T cell and tumor cell interaction with cytokines and checkpoint inhibitors",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "352d921a-381d-4a1d-b729-c85f324e10e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.58,
        "x": 0.38,
        "y": 0.23
      },
      "kind": "list",
      "text": "Checkpoint modulation has driven the growth of the IO field - $88 billion in sales projected by 2027. Only a minority of solid tumor patients experience a response to anti-PD-(L)1 therapy. Responders to existing immunotherapies often experience disease progression.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0caa8d1d-8079-4b35-8956-720053ca4b93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.58,
        "x": 0.38,
        "y": 0.42
      },
      "kind": "list",
      "text": "Cytokines are biologically active proteins that play an essential role in immune cell functions. In cancer, cytokines can help prime, expand, activate, and/or enhance activity of the immune system to recognize and eliminate tumor cells.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4dd4120-19cb-4290-b357-ccf66dde9b9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.58,
        "x": 0.38,
        "y": 0.55
      },
      "kind": "list",
      "text": "Mural Oncology focuses on optimizing immune cell activity, a key driver of immune response to cancer cells. EXPANSION: IL-2 expands tumor-killing immune cells. RESTORATION: IL-18 reinvigorates T cell exhaustion. ACTIVATION: IL-12 drives pro-inflammatory responses.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dabe5f89-6ec4-4836-a7a4-80758b424f99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.58,
        "x": 0.38,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Mural Oncology’s engineered cytokines may lead to new therapies for significant patient populations where checkpoint inhibitors failed to achieve a response or had a limited response",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a743f78-7f19-4f18-b3f3-68196d92592d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Extracted from Lei Q, et al. Front. Cell Dev. Biol. 2020;8:00672. 1. GlobalData Thematic Research: Immuno-Oncology",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b832bceb-1665-4166-8f2d-ccc778bdd8ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Cytokines Play an Important Role in Immuno-Oncology (IO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13d78fb2-e7e6-4ed7-a329-a05b1fdf98cc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "3ac1c689-f5a4-4697-9836-72c6ac79bd59",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 8-9 discuss the role of cytokines in immuno-oncology and their limitations.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b9e35abb-b37b-4734-a4e7-f370e28be28e",
      "evidence": "Slides 8-9 imply that current therapies have limitations and that Mural Oncology's solutions are needed.",
      "position": 0,
      "objective": "What are the consequences of not addressing the limitations of current cytokine therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}